ICYMI, some of the content featured this week includes articles about antihistamines for alopecia areata, treating pediatric patients with skin of color, topical roflumilast study results, racial disparities in melanoma survival, plus more.
In case you missed it, some of this week’s featured content includes articles about treating pediatric patients with skin of color, antihistamines for alopecia areata, positive results from a phase 2 study investigating topical roflumilast as a treatment for seborrheic dermatitis, racial disparities in melanoma survival, DefenAge launching a new neck cream, the United States Food and Drug Administration (FDA) expanding the indication for golimumab, plus more.
Adults with atopic dermatitis (AD) stay on dupilumab (Dupixent, Sanofi and Regeneron) significantly longer than on cyclosporine, according to a recent study.
Candrice Heath, M.D., shares her tips and tricks for treating young skin of color patients from her presentation at the 2020 Skin of Color Update.
In part two of our interview with Candrice Heath, M.D., she explains the most commonly encountered skin conditions when treating young skin of color patients.
A recent study published in the Journal of the American Academy of Dermatology found positive results when using antihistamines, along with topical corticosteroids and superficial cryotherapy, as a combination treatment for alopecia areata.
In the final part of our interview with Candrice Heath, M.D., she discusses some of the treatment challenges associated with treating pediatric patients with skin of color and how to overcome these obstacles.
Arcutis Biotherapeutics announces topline results from its recent phase 2 clinical study investigating topical roflumilast foam for the treatment of seborrheic dermatitis.
A new descriptor may help providers to differentiate melanoma from benign lesions, says authors of a recent study.
DefenAge announces the launches of their 6-Week Perfection Neck Cream, designed to improve the appearance of the neck by diminishing fine lines, folds and wrinkles.
ZILXI (FMX103, VYNE Therapeutics), a 1.5% topical minocycline foam, is now available for prescription for the treatment of inflammatory lesions of rosacea in adult patients.
Today's universal improvement in melanoma survival is encouraging. But the reality is racial disparities aren’t going away and in some cases are getting worse.
The U.S. FDA has approved to expand the indication for golimumab (SIMPONI ARIA, Janssen Pharmaceutical Companies of Johnson & Johnson) to include it was a treatment for active psoriatic arthritis (PsA) in pediatric patients 2 years and older.